Literature DB >> 32415560

Bronchoalveolar lavage findings in severe COVID-19 pneumonia.

Guillaume Voiriot1, Anne Fajac2, Julien Lopinto3, Vincent Labbé3, Muriel Fartoukh3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32415560      PMCID: PMC7225401          DOI: 10.1007/s11739-020-02356-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


× No keyword cloud information.

Introduction

A 82-year-old man presented with asthenia, dyspnea and fever for 2 days and was admitted from the emergency department to our intensive care unit with acute hypoxemic respiratory failure. His past medical history included a myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis with renal impairment, diagnosed 4 years earlier and treated with steroids and methotrexate for 2 years, resulting in a persistent chronic kidney disease. Following admission and endotracheal intubation for mechanical ventilation, a thoracic CT-scan (see Supplementary material) disclosed bilateral interstitial lung infiltrates, with multiple patterns including micronodules, ground-glass and tree-in-bud opacities. Bronchoalveolar lavage (BAL) was performed in the right middle lobe (75 mL/150 mL). Macroscopic examination of BAL fluid revealed a pink color; microscopic examination (Fig. 1) revealed a total cell count (220 cell/µL) in the normal range, but a high lymphocyte differential count (24%, CD3 82% and CD19 2%) with a CD4/CD8 T-cell ratio of 1.7. A complete microbiological workup was performed, which allowed to diagnose COVID-19 pneumonia, without concomitant bacterial infection. No recurrence of vasculitis was identified. Despite symptomatic treatment, the patient died after 13 days in the ICU. Here, we point out the high lymphocyte count in BAL fluid during COVID-19 pneumonia. Data about alveolar cellularity in this novel viral infection are urgently needed, which may provide clues for testing immunomodulatory treatments [1] in the most severely affected patients.
Fig. 1

May-Grunwald Giemsa stained cells from bronchoalveolar lavage fluid after cytocentrifugation (40X). Black arrow: lymphocyte; white arrow: macrophage; arrowhead: neutrophil

May-Grunwald Giemsa stained cells from bronchoalveolar lavage fluid after cytocentrifugation (40X). Black arrow: lymphocyte; white arrow: macrophage; arrowhead: neutrophil Below is the link to the electronic supplementary material. Supplementary file1 (TIF 1003 kb)
  1 in total

Review 1.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.

Authors:  James M Sanders; Marguerite L Monogue; Tomasz Z Jodlowski; James B Cutrell
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

  1 in total
  10 in total

1.  Bronchoalveolar lavage-detected SARS-CoV-2 infection in presence of serial negative nasopharyngeal swabs: a case report.

Authors:  Grazia Caci; Fabrizio Minervini; Carsten Fechner; Justus E Roos; Ellen C Obermann; Andrea Azzola
Journal:  Ann Transl Med       Date:  2021-04

Review 2.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

Review 3.  COVID-19-Associated Acute Respiratory Distress Syndrome: Lessons from Tissues and Cells.

Authors:  Elizabeth A Middleton; Guy A Zimmerman
Journal:  Crit Care Clin       Date:  2021-05-26       Impact factor: 3.598

4.  Low BALF CD4 T cells count is associated with extubation failure and mortality in critically ill covid-19 pneumonia.

Authors:  Gurmeet Singh; Cleopas Martin Rumende; Surendra K Sharma; Iris Rengganis; Zulkifli Amin; Tonny Loho; Emmy Hermiyanti; Kuntjoro Harimurti; Heri Wibowo
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

5.  Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes.

Authors:  Ian Gelarden; Jessica Nguyen; Juehua Gao; Qing Chen; Luisa Morales-Nebreda; Richard Wunderink; Lin Li; Joan S Chmiel; MaryAnn Hrisinko; Laura Marszalek; Sumaiya Momnani; Pinal Patel; Ricardo Sumugod; Qi Chao; Lawrence J Jennings; Teresa R Zembower; Peng Ji; Yi-Hua Chen
Journal:  Hum Pathol       Date:  2021-04-24       Impact factor: 3.526

6.  Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.

Authors:  Md Jahidul Hasan; Raihan Rabbani; Ahmad Mursel Anam; Shihan Mahmud Redwanul Huq; Mohammad Mufizul Islam Polash; Shahzadi Sayeeda Tun Nessa; Sitesh C Bachar
Journal:  BMC Infect Dis       Date:  2021-05-07       Impact factor: 3.090

7.  Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity.

Authors:  Mizanur Rahman; Martin Irmler; Sandeep Keshavan; Micol Introna; Johannes Beckers; Lena Palmberg; Gunnar Johanson; Koustav Ganguly; Swapna Upadhyay
Journal:  Viruses       Date:  2021-12-17       Impact factor: 5.048

8.  Cytopathological Findings in Bronchoalveolar Lavage from Patients with COVID-19.

Authors:  Silvio Antonio Galeano Reyes; Patricia Dhimes Tejeda; Bárbara Steen; Hansely Keret Arcos Orozco; Paloma Ramos Pontón
Journal:  Acta Cytol       Date:  2022-06-22       Impact factor: 3.000

Review 9.  Pathogenesis of COVID-19-induced ARDS: implications for an ageing population.

Authors:  Manuel A Torres Acosta; Benjamin D Singer
Journal:  Eur Respir J       Date:  2020-09-24       Impact factor: 16.671

10.  COVID-19 and BCG: where's the challenge?

Authors:  Georges Mjaess; Eddy Lilly; Raymond Mansour; Simone Albisinni; Elie Nemr; Fouad Aoun; Thierry Roumeguere
Journal:  World J Urol       Date:  2021-01-02       Impact factor: 3.661

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.